Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001759241Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationImage: Contact Information

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value			Name the Securities Exchange
Common	Merrill 555 California Street Floor 18 San Francisco CA 94104	24165	1011305.25	61111678	03/13/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date of Nature of Date you Nature of Name of Is Date Amount of Class Acquired Acquisition Person from this Donor **Securities Payment** Payment *

Kymera Therapeutics, Inc. 001-39460 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MASSACHUSETTS 02472 857-285-5314

Atlas Venture Opportunity Fund I, L.P.

	Transaction	Whom		Acquired	Acquired	
		Acquired	Gift?			
Common	03/11/2020 Private Placement	Issuer		2	24165	03/11/2020 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Venture Fund X LP 300 Technology Square Suite 8 Cambridge MA 02139	Common	03/11/2024	42302	1812379.95
Atlas Venture Opportunity Fund I, LP 300 Technology Square Suite 8 Cambridge MA 02139	Common	03/11/2024	8882	380538.95
Atlas Venture Fund X LP 300 Technology Square Suite 8 Cambridge MA 02139	Common	03/12/2024	134647	5651647.06
Atlas Venture Opportunity Fund I, LP 300 Technology Suite 8 Cambridge MA 02139	Common	03/12/2024	28271	1186641.47

144: Remarks and Signature

Remarks	
Date of Notice	03/13/2024
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/22/2024
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)